Luye Pharma Group Ltd.

2186

BMG570071099

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:09:05 07/06/2024 BST			5-day change	1st Jan Change
2.85 ^HKD	+1.79%		+6.34%	-23.59%

06-06	Luye Pharma's Japanese Partner Towa Files New Drug Application for Dementia Patch	MT
03-27	Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Luye Pharma Group Ltd. Announces Cessation of Chen Wende as Chief Operating Officer, with Effect from August 15, 2012

July 23, 2012 at 10:50 am

Luye Pharma Group Ltd. announced cessation of Chen WenDe as chief operating officer, with effect from August 15, 2012.

Latest news about Luye Pharma Group Ltd.

Luye Pharma's Japanese Partner Towa Files New Drug Application for Dementia Patch	06-06	MT
Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	03-07	CI
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug	03-04	MT
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610	03-04	CI
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%	02-02	MT
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States	02-01	CI
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List	12-13	MT
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval	12-13	MT
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	12-12	MT
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong	12-12	CI
Luye Pharma Group Ltd. Announces Board Changes	12-06	CI
Chinese Regulator Green Lights Luye Pharma’s Small Cell Lung Cancer Drug	12-04	MT
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	12-04	MT
China Gives Marketing Green Light to Luya Pharma's Patch Treatment for Alzheimer's Disease	11-01	MT
Luye Pharma Group Ltd. Announces Rivastigmine Twice Weekly Transdermal Patch Approval for Marketing in China	31/10/23	CI
Luye Pharma Files New Drug Application in US for Schizophrenia Medication	09/10/23	MT
Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder	09/10/23	CI
China Approves Luye Pharma's Breast Cancer Injectable	08/09/23	MT
Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio	07/09/23	CI
Luye Pharma Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23	CI
Luye Pharma Group Ltd. Submits New Drug Application for Lurbinectedin	21/08/23	CI
Luye Pharma's Rykindo Enters US Market; Shares Down 3%	18/08/23	MT
Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United States	17/08/23	CI
Chinese Regulator Accepts Luye Pharma's New Drug Application for Parkinson's Disease Injectable	02/08/23	MT

Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Companyâs main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimerâs disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Luye Pharma Group Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

2.644 CNY

Average target price

2.822 CNY

Spread / Average Target

+6.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LUYE PHARMA GROUP LTD.	-23.59%	1.37B
ELI LILLY AND COMPANY	+45.82%	765B
NOVO NORDISK A/S	+40.95%	632B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ASTRAZENECA PLC	+18.45%	248B
ROCHE HOLDING AG	-0.78%	219B
NOVARTIS AG	+11.88%	216B
AMGEN INC.	+5.90%	164B

Other Pharmaceuticals